Common questions about Seebri Breezhaler (FAQ)
Q: How quickly does Seebri Breezhaler start to work after the first dose?
A: Clinical trial data indicates that an improvement in lung function is generally seen rapidly after the first dose. According to the official product information, some studies noted the onset of effect within five to twenty minutes following initial use.
Q: What evidence is there that Seebri Breezhaler improves quality of life or exercise tolerance?
A: Studies and official information indicate that patients experienced improvements in measures of breathlessness (Transition Dyspnea Index) and overall health status. Clinical trial results indicated that patients experienced improved exercise endurance when compared to placebo groups.
Q: What happens if I accidentally inhale the capsule powder without hearing the 'click'?
A: The piercing sound, or 'click', is a feedback mechanism that confirms the capsule has been successfully opened. If the sound is not heard, the user should check the capsule after inhalation. If powder remains inside, official instructions advise repeating the inhalation process.
Q: Can patients with liver problems (hepatic impairment) use Seebri Breezhaler?
A: Official information states that no specific studies have been conducted in patients with hepatic (liver) impairment. However, because the medicine is primarily cleared by the kidneys, a major increase in the drug’s exposure in the body is not expected. Based on this information, dose adjustment is not expected to be required.
Q: Does Seebri Breezhaler provide 24-hour symptom relief?
A: Official documents describe this medicine as a long-acting bronchodilator. Clinical data from trials indicated that the bronchodilation benefit was sustained for 24 hours over the maintenance treatment period.
Q: Can Seebri Breezhaler be used for conditions other than COPD, like asthma?
A: Seebri Breezhaler is approved for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults to relieve symptoms. The medicine is not indicated or approved for the treatment of asthma or other respiratory conditions.
Q: Is it common to feel a mild cough or throat irritation after using the Breezhaler device?
A: Throat irritation is listed as an uncommon adverse drug reaction in official documents. Patient instructions indicate that a cough after inhalation may occur, but it does not affect the dose received if the capsule is empty afterward.
Q: What is the 'whirring sound' I'm supposed to hear when I use the inhaler?
A: The whirring sound is a feedback mechanism specific to the Breezhaler device. It confirms that the patient has inhaled quickly and deeply enough to properly release the medicine powder from the capsule for delivery to the lungs.
Q: What should I do if the capsule is stuck in the Breezhaler device?
A: If the capsule becomes stuck, official device instructions advise carefully loosening the capsule by gently tapping the base of the inhaler. The patient instructions then advise repeating the inhalation process to ensure the dose is delivered.
Q: Are there any common long-term side effects associated with Seebri Breezhaler use?
A: Clinical trials tracked the safety profile of the medicine for up to 52 weeks (one year). The most frequently reported adverse event observed during this long-term period was dry mouth, which is consistent with other medicines in the same class.
Q: Is dry mouth a common side effect, and does it go away over time?
A: Dry mouth is the most frequently reported anticholinergic adverse reaction in clinical trials (a common side effect). It was generally reported to be of mild degree, but official documents do not include specific information on whether dry mouth diminishes over time.
Q: Is Seebri Breezhaler safe for use during pregnancy or while breastfeeding?
A: The use of Seebri Breezhaler is generally not recommended during pregnancy or while breastfeeding, as it is unknown whether the active ingredient passes into breast milk. This aligns with official product information.
Q: Does Seebri Breezhaler have any potential effect on heart rhythm or heart rate?
A: At the recommended dosage, the medicine is described in official documents as being devoid of effects on blood pressure or heart rate. However, regulatory warnings indicate that caution is advised for use in patients with pre-existing heart conditions, particularly certain types of arrhythmia (irregular heartbeats).
Q: Do I need to rinse my mouth after using the Seebri Breezhaler?
A: Official patient instructions advise rinsing the mouth with water and spitting the water out after using the inhaler.
Q: Does Seebri Breezhaler cause increased urination or difficulty passing urine?
A: Difficulty passing urine (such as urinary retention or painful urination) is listed as an uncommon side effect. Increased or frequent urination is also reported as a possible sign of a different, uncommon side effect (high blood sugar).
Q: Is the Breezhaler device complicated to use compared to other inhalers?
A: The Breezhaler device is designed with low airflow resistance. This feature may help patients with varying degrees of COPD severity more easily achieve the required quick, deep inhalation flow rate for effective delivery of the medicine to the lungs.
Q: Can the powder residue be seen in the capsule after a successful inhalation?
A: After inhalation, patients are advised to check the capsule to ensure it is empty or near-empty. If powder remains, patient instructions advise repeating the inhalation steps.
Q: Are there any known interactions with over-the-counter cold or flu medications?
A: While specific over-the-counter medicines are not individually listed, the co-administration of Seebri Breezhaler with other inhaled anticholinergic-containing drugs is not recommended. This is due to the potential for an increase in anticholinergic-related side effects.
Q: What is the shelf life of the Seebri capsules?
A: The capsules have a manufacturer-stated shelf life (e.g., up to two years) before their expiry date. The inhaler device itself should be disposed of after all capsules in the pack have been used, or after a maximum of 30 days of use, whichever comes first, according to official disposal protocols.
Q: Why are the capsules stored inside a foil blister pack instead of a bottle?
A: Official storage instructions require that the capsules must always be stored in the original blister packaging to protect them from moisture and light. This protection is necessary to ensure the quality of the inhalation powder for proper delivery.
Q: Can Seebri Breezhaler affect blood pressure?
A: At the recommended dosage, official documents describe the medicine as being devoid of effects on blood pressure or heart rate. This information is based on the results from clinical trials.
Q: Is it normal to feel a change in taste after using the inhaler?
A: A change in taste (dysgeusia) has been reported in post-marketing experience with the active ingredient (glycopyrronium), though it was not listed as a common or uncommon side effect in the main clinical trials.
Q: Is there a risk of developing a cough or lung infection while on Seebri Breezhaler?
A: Infections of the upper airways, such as nasopharyngitis (cold-like symptoms), sinusitis, and rhinitis, have been reported as common or uncommon side effects in clinical trials.
Q: Can Seebri Breezhaler make my vision blurry?
A: As an anticholinergic medicine, there is a possibility of experiencing effects like transient blurred vision. Regulatory warnings advise consulting a healthcare provider immediately if any visual changes occur.
Q: Do I need to clean the Breezhaler device, and if so, how?
A: The Breezhaler device must not be washed with water. If cleaning is needed, the mouthpiece can be gently wiped with a dry cloth or tissue only, as specified in patient instructions.
Q: Is it required to keep using my other COPD medications when starting Seebri Breezhaler?
A: The co-administration of Seebri Breezhaler with other inhaled anticholinergic-containing drugs is not recommended. The continued use of other classes of maintenance COPD medicines should be determined by a healthcare provider based on the individual treatment plan.
Q: Are headaches a common side effect when starting Seebri Breezhaler?
A: Yes, headache is listed as a common side effect in official documents, meaning it may affect up to 1 in 10 people reported during clinical trials.
Q: Can the use of this drug lead to a worsening of my COPD symptoms over time?
A: Clinical trial data indicated that treatment was associated with a reduced annual rate of moderate to severe COPD exacerbations compared to placebo. However, the medicine may rarely cause an immediate, acute worsening of breathing called paradoxical bronchospasm upon inhalation, which requires immediate medical attention.
